NCT06657391View on ClinicalTrials.gov

Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

396

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Transfusion Dependent Thalassemia

Interventions

DRUG

recombinant humanized anti-CD25 monoclonal antibody

The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.

Trial Locations (5)

525000

RECRUITING

Maoming People's Hospital, Maoming

530000

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

537000

RECRUITING

Yulin Red Cross Hospital, Yulin

545007

RECRUITING

Liuzhou Workers' Hospital, Liuzhou

570000

RECRUITING

Hainan Provincial People's Hospital, Haikou

All Listed Sponsors

lead

Rongrong Liu

OTHER